Bavarian Nordic has now commenced the planned Phase I study of MVABN RSV. Advancing the earlier-stage pipeline is one of Bavarian Nordic’s key priorities, hence this represents an important step. RSV could be a significant opportunity, particularly in adults, and we expect Bavarian to consider partnering, albeit not until at least Phase II. Our valuation, which does not yet include RSV owing to its early stage of development, is largely unchanged at DKK12.6bn.
21 Aug 2015
Advancing the pipeline with start of RSV trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Advancing the pipeline with start of RSV trial
Bavarian Nordic has now commenced the planned Phase I study of MVABN RSV. Advancing the earlier-stage pipeline is one of Bavarian Nordic’s key priorities, hence this represents an important step. RSV could be a significant opportunity, particularly in adults, and we expect Bavarian to consider partnering, albeit not until at least Phase II. Our valuation, which does not yet include RSV owing to its early stage of development, is largely unchanged at DKK12.6bn.